Nindanib 150mg Capsule

About

Nindanib 150mg Capsule is a multi-targeted tyrosine kinase inhibitor (TKI) that acts by blocking several key signaling pathways involved in the pathogenesis of various diseases, including cancer and fibrotic conditions. Its primary targets include vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-3), and platelet-derived growth factor receptors (PDGFR α/β). By inhibiting these receptors, Nindanib effectively suppresses angiogenesis (the formation of new blood vessels that supply tumors), inhibits the proliferation of cancer cells, and reduces the progression of fibrotic processes in affected tissues.

This broad-spectrum inhibition makes Nindanib 150mg Capsule a valuable therapeutic option for conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and certain types of advanced non-small cell lung cancer (NSCLC). Its mechanism of action helps to slow disease progression and improve patient outcomes by disrupting multiple critical pathways. Due to its systemic effects, careful monitoring for potential adverse reactions, particularly gastrointestinal disturbances and liver enzyme elevations, is essential throughout the treatment period to ensure patient safety and optimize therapeutic benefits.

Uses

• Treatment of idiopathic pulmonary fibrosis (IPF).
• Management of advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology.
• Treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• Therapy for chronic fibrosing interstitial lung diseases with a progressive phenotype.

Directions For Use

Take Nindanib 150mg Capsule orally twice daily, approximately 12 hours apart, with food, as directed by your physician. Swallow the capsule whole; do not chew or crush it.

Benefits

• Inhibits multiple growth factor receptors.
• Reduces angiogenesis and fibrosis.
• Slows disease progression in IPF and SSc-ILD.
• Effective in specific types of NSCLC.
• May improve lung function.
• Offers a targeted therapeutic option.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Decreased appetite
• Weight loss
• Liver enzyme elevation
• Fatigue
• Headache
• Hypertension
• Rash
• Proteinuria

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may increase the risk of liver enzyme elevation and other gastrointestinal side effects.
• Pregnancy - Nindanib 150mg Capsule is contraindicated during pregnancy due to potential embryofetal toxicity. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment with Nindanib 150mg Capsule and for at least 3 days after the last dose, as the drug may be excreted in breast milk.
• Liver - Use with extreme caution in patients with hepatic impairment; dose adjustments are necessary, and liver function should be monitored closely and regularly.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment, but caution is advised in severe cases.
• Lung - Monitor for new or worsening respiratory symptoms, especially in patients with pre-existing lung conditions, though it is used for lung fibrosis.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.